Genomic analysis between idiopathic pulmonary fibrosis and associated lung cancer using laser‐assisted microdissection: A case report

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with unclear pathogenesis. IPF is considered as a risk factor for lung cancer. Compared to other lung cancers, small-cell lung cancer (SCLC) has a lower incidence, but has a more aggressive course. Patients with IPF and SCLC have a lower survival rate, more difficult treatment, and poorer prognosis. Case presentation Case 1 was of a 66-year-old man with IPF for 5 years, who was admitted to our hospital for dyspnea. Case 2 was of a 68-year-old woman, who presented with chest pains, cough, and dyspnea. Both patients had extremely poor lung function. High-resolution computed tomography and pathology revealed that both patients had IPF and SCLC. Chemotherapy comprising nedaplatin (80 mg/m2) and etoposide (100 mg for 5 days) was initiated for both patients. Antifibrotic agents were continued during the chemotherapeutic regimen. Both patients showed improvement in their condition after treatment. Conclusion The favorable outcomes in these 2 cases suggests that chemotherapy is worth considering in the management of patients having SCLC and IPF with poor lung function.

Download Full-text

Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes

Surgery Today ◽

10.1007/s00595-021-02343-0 ◽

2021 ◽

Author(s):

Akira Iyoda ◽

Yoko Azuma ◽

Susumu Sakamoto ◽

Sakae Homma ◽

Atsushi Sano

Keyword(s):

Lung Cancer ◽

Surgical Treatment ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Acute Exacerbation

Download Full-text

Overexpression Of Matrix Metalloproteinases In Bronchoalveolar Lavage Fluid (BALF) And Lung Tissue Of Non-Small Cell Lung Cancer (NSCLC) Patients: Comparison With Idiopathic Pulmonary Fibrosis (IPF)

10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4427 ◽

2012 ◽

Author(s):

Katerina D. Samara ◽

Konstantinos Karagiannis ◽

Ismini Lasithiotaki ◽

Irini Lambiri ◽

Nikolaos M. Siafakas ◽

...

Keyword(s):

Lung Cancer ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Bronchoalveolar Lavage ◽

Small Cell Lung Cancer ◽

Bronchoalveolar Lavage Fluid ◽

Lavage Fluid ◽

Small Cell ◽

Small Cell Lung ◽

Nsclc Patients

Download Full-text

Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis

Scientific Reports ◽

10.1038/s41598-021-92098-y ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Yasuto Yoneshima ◽

Eiji Iwama ◽

Shingo Matsumoto ◽

Taichi Matsubara ◽

Testuzo Tagawa ◽

...

Keyword(s):

Lung Cancer ◽

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Lung Adenocarcinoma ◽

Genetic Alterations ◽

Driver Mutations ◽

Somatic Variant ◽

Tumor Mutation Burden ◽

Mutation Burden ◽

And Oxidative Stress

AbstractGenetic alterations underlying the development of lung cancer in individuals with idiopathic pulmonary fibrosis (IPF) have remained unclear. To explore whether genetic alterations in IPF tissue contribute to the development of IPF-associated lung cancer, we here evaluated tumor mutation burden (TMB) and somatic variants in 14 paired IPF and tumor samples from patients with IPF-associated lung adenocarcinoma. We also determined TMB for 22 samples of lung adenocarcinoma from patients without IPF. TMB for IPF-associated lung adenocarcinoma was significantly higher than that for matched IPF tissue (median of 2.94 vs. 1.26 mutations/Mb, P = 0.002). Three and 102 somatic variants were detected in IPF and matched lung adenocarcinoma samples, respectively, with only one pair of specimens sharing one somatic variant. TMB for IPF-associated lung adenocarcinoma was similar to that for lung adenocarcinoma samples with driver mutations (median of 2.94 vs. 2.51 mutations/Mb) and lower than that for lung adenocarcinoma samples without known driver mutations (median of 2.94 vs. 5.03 mutations/Mb, P = 0.130) from patients without IPF. Our findings suggest that not only the accumulation of somatic mutations but other factors such as inflammation and oxidative stress might contribute to the development and progression of lung cancer in patients with IPF.

Download Full-text